Literature DB >> 18541670

Mdm2 promotes genetic instability and transformation independent of p53.

Alyssa Bouska1, Tamara Lushnikova, Silvia Plaza, Christine M Eischen.   

Abstract

Mdm2, a regulator of the tumor suppressor p53, is frequently overexpressed in human malignancies. Mdm2 also has unresolved, p53-independent functions that contribute to tumorigenesis. Here, we show that increased Mdm2 expression induced chromosome/chromatid breaks and delayed DNA double-strand break repair in cells lacking p53 but not in cells with a mutant form of Nbs1, a component of the Mre11/Rad50/Nbs1 DNA repair complex. A 31-amino-acid region of Mdm2 was necessary for binding to Nbs1. Mutation of conserved amino acids in the Nbs1 binding domain of Mdm2 inhibited Mdm2-Nbs1 association and prevented Mdm2 from delaying phosphorylation of H2AX and ATM-S/TQ sites, repair of DNA breaks, and resolution of DNA damage foci. Similarly, the mutation of eight amino acids in the Mdm2 binding domain of Nbs1 inhibited Mdm2-Nbs1 interaction and blocked the ability of Mdm2 to delay DNA break repair. Both Nbs1 and ATM, but not the ubiquitin ligase activity of Mdm2, were necessary to inhibit DNA break repair. Only Mdm2 with an intact Nbs1 binding domain was able to increase the frequency of chromosome/chromatid breaks and the transformation efficiency of cells lacking p53. Therefore, the interaction of Mdm2 with Nbs1 inhibited DNA break repair, leading to chromosome instability and subsequent transformation that was independent of p53.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18541670      PMCID: PMC2493369          DOI: 10.1128/MCB.01584-07

Source DB:  PubMed          Journal:  Mol Cell Biol        ISSN: 0270-7306            Impact factor:   4.272


  55 in total

Review 1.  DNA damage and repair in individual cells: applications of the comet assay in radiobiology.

Authors:  P L Olive
Journal:  Int J Radiat Biol       Date:  1999-04       Impact factor: 2.694

2.  Nbs1 potentiates ATP-driven DNA unwinding and endonuclease cleavage by the Mre11/Rad50 complex.

Authors:  T T Paull; M Gellert
Journal:  Genes Dev       Date:  1999-05-15       Impact factor: 11.361

3.  ATM activation by DNA double-strand breaks through the Mre11-Rad50-Nbs1 complex.

Authors:  Ji-Hoon Lee; Tanya T Paull
Journal:  Science       Date:  2005-03-24       Impact factor: 47.728

Review 4.  MDM2 and human malignancies: expression, clinical pathology, prognostic markers, and implications for chemotherapy.

Authors:  Elizabeth Rayburn; Ruiwen Zhang; Jie He; Hui Wang
Journal:  Curr Cancer Drug Targets       Date:  2005-02       Impact factor: 3.428

5.  Loss of one but not two mdm2 null alleles alters the tumour spectrum in p53 null mice.

Authors:  T J McDonnell; R Montes de Oca Luna; S Cho; L L Amelse; A Chavez-Reyes; G Lozano
Journal:  J Pathol       Date:  1999-07       Impact factor: 7.996

6.  A single nucleotide polymorphism in the MDM2 promoter attenuates the p53 tumor suppressor pathway and accelerates tumor formation in humans.

Authors:  Gareth L Bond; Wenwei Hu; Elisabeth E Bond; Harlan Robins; Stuart G Lutzker; Nicoleta C Arva; Jill Bargonetti; Frank Bartel; Helge Taubert; Peter Wuerl; Kenan Onel; Linwah Yip; Shih-Jen Hwang; Louise C Strong; Guillermina Lozano; Arnold J Levine
Journal:  Cell       Date:  2004-11-24       Impact factor: 41.582

7.  Centrosome hyperamplification in human cancer: chromosome instability induced by p53 mutation and/or Mdm2 overexpression.

Authors:  P E Carroll; M Okuda; H F Horn; P Biddinger; P J Stambrook; L L Gleich; Y Q Li; P Tarapore; K Fukasawa
Journal:  Oncogene       Date:  1999-03-18       Impact factor: 9.867

Review 8.  p53-independent functions of MDM2.

Authors:  Gitali Ganguli; Bohdan Wasylyk
Journal:  Mol Cancer Res       Date:  2003-12       Impact factor: 5.852

9.  Megabase chromatin domains involved in DNA double-strand breaks in vivo.

Authors:  E P Rogakou; C Boon; C Redon; W M Bonner
Journal:  J Cell Biol       Date:  1999-09-06       Impact factor: 10.539

10.  Myc signaling via the ARF tumor suppressor regulates p53-dependent apoptosis and immortalization.

Authors:  F Zindy; C M Eischen; D H Randle; T Kamijo; J L Cleveland; C J Sherr; M F Roussel
Journal:  Genes Dev       Date:  1998-08-01       Impact factor: 11.361

View more
  58 in total

1.  MDM2 SNP309 is an ethnicity-dependent risk factor for digestive tract cancers.

Authors:  Bo Chen; Lei Cao; Kong-Wang Hu; Jia-Wei Zhang; Xiang-Ling Meng; Mao-Ming Xiong
Journal:  Tumour Biol       Date:  2013-12-13

Review 2.  Role of E3 ubiquitin ligases in gastric cancer.

Authors:  Ya-Chao Hou; Jing-Yu Deng
Journal:  World J Gastroenterol       Date:  2015-01-21       Impact factor: 5.742

3.  Nutlin-3, an Antagonist of MDM2, Enhances the Radiosensitivity of Esophageal Squamous Cancer with Wild-Type p53.

Authors:  Tianli He; Jiayou Guo; Hongmei Song; Hongcheng Zhu; Xiaoke Di; Hua Min; Yuandong Wang; Guangzong Chen; Wangshu Dai; Jianhua Ma; Xinchen Sun; Jianxin Ma
Journal:  Pathol Oncol Res       Date:  2017-03-24       Impact factor: 3.201

Review 4.  Genome Stability Requires p53.

Authors:  Christine M Eischen
Journal:  Cold Spring Harb Perspect Med       Date:  2016-06-01       Impact factor: 6.915

5.  Mdm4 supports DNA replication in a p53-independent fashion.

Authors:  Kai Wohlberedt; Ina Klusmann; Polina K Derevyanko; Kester Henningsen; Josephine Ann Mun Yee Choo; Valentina Manzini; Anna Magerhans; Celeste Giansanti; Christine M Eischen; Aart G Jochemsen; Matthias Dobbelstein
Journal:  Oncogene       Date:  2020-05-19       Impact factor: 9.867

6.  Potentiation of Carboplatin-Mediated DNA Damage by the Mdm2 Modulator Nutlin-3a in a Humanized Orthotopic Breast-to-Lung Metastatic Model.

Authors:  Eva Tonsing-Carter; Barbara J Bailey; M Reza Saadatzadeh; Jixin Ding; Haiyan Wang; Anthony L Sinn; Kacie M Peterman; Tiaishia K Spragins; Jayne M Silver; Alyssa A Sprouse; Taxiarchis M Georgiadis; T Zachary Gunter; Eric C Long; Robert E Minto; Christophe C Marchal; Christopher N Batuello; Ahmad R Safa; Helmut Hanenberg; Paul R Territo; George E Sandusky; Lindsey D Mayo; Christine M Eischen; Harlan E Shannon; Karen E Pollok
Journal:  Mol Cancer Ther       Date:  2015-10-22       Impact factor: 6.261

7.  DNA damage response to the Mdm2 inhibitor nutlin-3.

Authors:  Rajeev Verma; Marc J Rigatti; Glenn S Belinsky; Cassandra A Godman; Charles Giardina
Journal:  Biochem Pharmacol       Date:  2010-02-15       Impact factor: 5.858

8.  Using Mouse Models to Explore MDM-p53 Signaling in Development, Cell Growth, and Tumorigenesis.

Authors:  Hugh S Gannon; Stephen N Jones
Journal:  Genes Cancer       Date:  2012-03

9.  ATM polymorphisms predict severe radiation pneumonitis in patients with non-small cell lung cancer treated with definitive radiation therapy.

Authors:  Huihua Xiong; Zhongxing Liao; Zhensheng Liu; Ting Xu; Qiming Wang; Hongliang Liu; Ritsuko Komaki; Daniel Gomez; Li-E Wang; Qingyi Wei
Journal:  Int J Radiat Oncol Biol Phys       Date:  2012-11-12       Impact factor: 7.038

10.  Protecting the genome from mdm2 and mdmx.

Authors:  Alexia N Melo; Christine M Eischen
Journal:  Genes Cancer       Date:  2012-03
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.